Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print New appropriate use criteria guide treatment of patients with heart blockage

New appropriate use criteria guide treatment of patients with heart blockage

January 06, 2009

Practical tool aids physicians, patients, payers

If you're committed to fitness, the decision to climb a couple of flights of stairs rather than take the elevator is clear. But if you develop chest pain on the way up, deciding how to treat the symptoms of clogged arteries in your heart is much more complicated.




Whether it's appropriate to treat chest pain with medical therapy alone or prescribe medical therapy and also perform revascularization-that is, by restoring good blood flow to the heart muscle with a balloon-tipped catheter or bypass surgery-depends on several factors that vary from patient to patient. In some cases the decision is obvious; in others, it's more nuanced.

Now physicians, patients and health insurers have a practical tool for weighing each of those factors and arriving at the right treatment decision. The new document, titled "Appropriate Use Criteria for Coronary Revascularization," appears in the February 10, 2009, issue of the Journal of the American College of Cardiology (JACC) and online at www.acc.org. The document will also be published in the January 5, 2009, online issues of Catheterization and Cardiovascular Interventions (CCI) and Circulation: Journal of the American Heart Association, and online at www.scai.org.

"One of the strengths of this document is that it provides a framework for thinking about clinical scenarios and having a discussion about coronary revascularization," said Manesh R. Patel, M.D., chair of the appropriate use criteria writing group and an assistant professor of medicine at Duke University and the Duke Clinical Research Institute in Durham, NC. "These recommendations describe when coronary revascularization would be expected to improve a patient's health status."

The new appropriate use criteria are the first to focus on cardiac treatment, rather than on diagnostic testing. They were jointly developed by the American College of Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and American Society of Nuclear Cardiology. They have been endorsed by the American Society of Echocardiography, Heart Failure Society of America, and Society of Cardiovascular Computed Tomography.

Appropriate use criteria differ from clinical guidelines both in their purpose and their format. While guidelines provide a comprehensive summary of evidence from clinical trials, appropriate use criteria focus on the types of patients cardiologists see in the clinic and hospital every day. Clinical studies may not have included such patients and, therefore, scientific evidence may not be readily available. Appropriate use criteria also present information in easily understood clinical scenarios that characterize patients according to four critical features:

* The severity and type of symptoms;
* How much cholesterol plaque has built up and in which arteries;
* How much of the heart muscle, according to stress testing, is being starved for blood and oxygen (a condition known as ischemia); and
* Whether the patient is already taking the right heart medications in the right dosages.

In developing the appropriate use criteria, a 17-member technical panel made up of general cardiologists, interventional cardiologists, cardiac surgeons, internal medicine specialists, health services researchers and others sifted through approximately 180 clinical scenarios, scoring each according to whether revascularization was appropriate, inappropriate or uncertain.

"This was quite a serious undertaking," said Peter K. Smith, M.D., a cardiac surgeon member of the writing committee on behalf of The Society of Thoracic Surgeons. "The process involved extensive review and debate of the available body of evidence, and resulted in remarkable consensus between specialties." Dr. Smith is also professor and chief of cardiothoracic surgery at Duke University.

Revascularization was considered appropriate if the expected improvements in survival, symptoms, functional status and/or quality of life outweighed the possible risks. In most cases, the panel considered revascularization as either bypass surgery or a catheter procedure (also known as percutaneous coronary intervention, or PCI). Because evidence is available to support either procedure for patients with advanced coronary disease, each method of revascularization was independently rated.

The panel determined that revascularization would be inappropriate in a patient who had plaque build-up in one or two arteries, experienced symptoms only during heavy exercise, had a small amount of heart muscle at risk, and was not taking medication to help control symptoms. However, they deemed revascularization appropriate if a similar patient had severe symptoms despite already taking the best available heart medication.

Appropriate use criteria are not intended to diminish the importance of clinical judgment in evaluating individual patients, nor to include every possible type of patient. Instead, one of their most important uses will be in evaluating patterns of care, and in helping to reduce the large variation in rates of revascularization that has been observed throughout the country.

"For physicians who look at the appropriate use criteria and conclude that 95 to 100 percent of the revascularization procedures they perform would be graded as appropriate-terrific," said Gregory J. Dehmer, M.D., a writing committee member and past president of the Society for Cardiovascular Angiography and Interventions. "But for those who find that only 60 or 70 percent of their procedures are appropriate and the rest are inappropriate, this document provides a very powerful message and gives them a benchmark for improving their practice." Dr. Dehmer is also a professor of medicine at Texas A & M University College of Medicine and cardiology director at Scott & White Clinic, both in Temple, TX.

It is also hoped that health insurers will use the appropriate use criteria in developing consistent payment and preauthorization policies and in conducting quality reviews.

"In the arena of cardiovascular science, we have a fair amount of data on revascularization and its ability to improve how patients feel or long they live," Dr. Patel said. "As a group that includes general cardiologists, interventionalists and surgeons, we're saying: For these common clinical scenarios, here is when it's appropriate-in most patients-to perform revascularization."

American College of Cardiology



Related Revascularization Current Events and Revascularization News Articles Revascularization Current Events and Revascularization News RSS Revascularization Current Events and Revascularization News RSS
Drug-eluting stents better than bare-metal stents for heart attack patients
Late-breaking data from the landmark HORIZONS-AMI clinical trial, presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, demonstrated that after two years, in heart attack patients, the use of a drug-eluting stent (paclitaxel) was safer and more effective than a bare-metal stent; and that the administration of the anticoagulant medication bivalirudin enhanced safety and efficacy compared to the use of heparin + GPIIb/IIIa inhibitors.

SPIRIT IV trial shows everolimus stent sets new standard for event-free survival
Late-breaking data from SPIRIT IV, a large-scale multi-center study of nearly 4,000 patients in the U.S., shows that an everolimus-eluting stent demonstrated enhanced safety and efficacy in the treatment of de novo native coronary artery lesions when compared to a paclitaxel-eluting stent, and showed that "low late loss" may be achieved with drug-eluting stents without sacrificing safety.

Drug-eluting stents safe, effective for treatment of chronic total occlusions
A multicenter study in Asia found drug-eluting stents effective with a low rate of acute complications in patients with chronic total occlusions (CTOs) undergoing PCI. Results of the study will be presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).

Researchers find drug-eluting stents safe, effective for PCI in diabetics
Results of a multicenter study in Asia, demonstrating that drug-eluting stents are effective with a low rate of complications in diabetic patients, will be presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).

New sensitive markers to detect myocardial infarction
New biomarkers significantly improve the early detection of acute myocardial infarction (AMI). Recent studies reveal a novel and promising way for doctors to conclusively ensure that a patient is having or not having an AMI in a timely and accurate manner saving time and money.

Emergency physician judgment on chest pain patients syncs with their outcomes
Emergency physicians should trust their judgment when evaluating patients who report with chest pain symptoms, said a group of researchers led by Abhinav Chandra, M.D., at Duke University Medical Center.

Early heart attack therapy with bone marrow extract improves cardiac function
A UCSF study for the treatment of heart failure after heart attack found that the extract derived from bone marrow cells is as effective as therapy using bone marrow stem cells for improving cardiac function, decreasing the formation of scar tissue and improving cardiac pumping capacity after heart attack.

Analysis of drug-eluting stents data demonstrates safety, efficacy in on-and-off-label use
The Cardiovascular Research Foundation (CRF) announced that results of the largest meta-analysis to date comparing mortality rates for drug-eluting stents (DES) versus bare metal stents (BMS) were published online June 15 in the journal Circulation.

Death rates same for diabetes and heart disease patients receiving drug therapy or surgery
There is no difference in mortality among patients with type 2 diabetes and stable heart disease who received prompt bypass surgery or angioplasty compared to drug therapy alone, according to a landmark study focused exclusively on patients with both conditions.

NEJM study finds drug-eluting stents more effective than bare-metal stents in heart attack patients
NewYork-Presbyterian Hospital and Columbia University Medical Center, together with the Cardiovascular Research Foundation (CRF), announced that its landmark study comparing the safety and efficacy of drug-eluting stents and bare-metal stents was published in the May 7 New England Journal of Medicine.
More Revascularization Current Events and Revascularization News Articles
Angiogenesis and Direct Myocardial Revascularization (Contemporary Cardiology)

Angiogenesis and Direct Myocardial Revascularization (Contemporary Cardiology)
by Roger J. Laham (Editor), Donald S. Baim (Editor)

An interdisciplinary panel of pioneers and opinion leaders review the basic, preclinical, clinical, and developmental pathways to new treatment strategies, such as therapeutic angiogenesis and myogenesis. The authors take advantage of new biological understanding, novel therapeutic targets, multiple available and well-studied therapeutic strategies, and the necessary imaging techniques to measure outcomes. Their in-depth discussions cover the identification of new therapeutic targets and pathways, the investigation of transcriptional factors, master switch molecules, cell-based approaches, chemokines, a better understanding of the effects of aging, endothelial dysfunction, and hypercholesterolemia in response to angiogenic stimuli. Highlights include examination of drug delivery problems,...

  Myocardial Revascularization: A Surgical Atlas
by Quentin R. Stiles (Author), Bernard L. Tucker (Author)



  Small Vessel Bypass Procedures and Maximum Revascularization: Surgery and Narration by John B. Chang, M.D., F.A.C.S.

1985 video tape.

  Acute Revascularization of the Infarcted Heart (A Society of Cardiovascular Anesthesiologists Monograph)
by J. G. Reves (Editor)



Myocardial Laser Revascularization

Myocardial Laser Revascularization
by Charles Bridges (Editor), Ray Chu-Jeng Chiu (Editor), Keith Horvath (Editor)

Myocardial Laser Revascularization

Edited by

Charles Bridges, MD, ScD

Chief of Cardiothoracic Surgery, University of Pennsylvania Health System, Philadelphia, PA, USA

Keith A. Horvath, MD

Chief, Cardiothoracic Surgery Branch, National Heart, Lung and Blood Institute, NIH, Bethesda, MD, USA

Ray Chu-Jeng Chiu, MD, PhD, FRCSC

Professor of Surgery and Chair Emeritus, McGill University, Montreal General Hospital, Montreal, Quebec, Canada

Finally, there is a dependable guide to transmyocardial laser revasculariztion (TMR). In this groundbreaking volume, clinicians who pioneered the use of this innovative treatment share their insights on the indications, results, mechanisms, and limitations of the technique.

Under the careful editorial...

  Myocardial Revascularization in Acute Conditions: Medico-Surgical Aspects (Bibliotheca Cardiologica)
by S. G. Degre (Editor)



  Transmyocardial Laser Revascularization: Present Status and Developments
by T. Krabatsch (Editor), Roland Hetzer (Editor)



High Risk Cardiac Revascularization and Clinical Trials

High Risk Cardiac Revascularization and Clinical Trials
by Douglass A. Morrison (Editor), Patrick W. Serruys (Editor)

Since the first coronary angioplasty procedure was carried out in 1977, there have been many developments in the field of interventional cardiology. As technologies and technique have evolved, the subset of patients considered suitable for percutaneous intervention has correspondingly widened, and non-surgical therapies have become both accepted practice and viable alternatives to surgical myocardial revascularization. Over the years several trials have been designed to test the success of these therapies for patients with multi-vessel obstructive coronary artery disease, and to compare survival rates with those receiving surgical treatment (namely coronary bypass surgery). However, early trials did not include higher-risk patients, the defining features of whom include older age,...

  Percutaneous Myocardial Revascularization.: An article from: Family Practice News
by Bruce Jancin (Author)

This digital document is an article from Family Practice News, published by International Medical News Group on March 1, 2000. The length of the article is 563 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Percutaneous Myocardial Revascularization.
Author: Bruce Jancin
Publication: Family Practice News (Magazine/Journal)
Date: March 1, 2000
Publisher: International Medical News Group
Volume: 30 Issue: 5 Page: 13

Distributed by Thomson...

  Female physicians refer fewer women for revascularization. (Gender Bias Across Genders).: An article from: Internal Medicine News
by Bruce Jancin (Author)

This digital document is an article from Internal Medicine News, published by International Medical News Group on January 15, 2002. The length of the article is 1443 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Female physicians refer fewer women for revascularization. (Gender Bias Across Genders).
Author: Bruce Jancin
Publication: Internal Medicine News (Magazine/Journal)
Date: January 15, 2002
Publisher: International Medical News Group
Volume: 35 Issue: 2 Page: 19(1)

Distributed by Thomson...

© 2009 BrightSurf.com